For the Dec-20 quarter, the consolidated operating profits were up 27.58% at Rs239.27cr. The company actually had a more than proportionate rise in cost of materials consumed due to persistent supply chain disruptions. As a result of higher cost of materials, the OPM contracted from 29.03% in the Dec-19 quarter to 27.84% in Dec-20 quarter.
Consolidated Profit after tax (PAT) for the Dec-20 quarter was up 32.45% at Rs204.11cr on better operational performance in the quarter, led by volume growth. PAT margins fell marginally from 23.86% in Dec-19 to 23.75% in Dec-20.
Financial highlights for Dec-20 compared yoy and sequentially
|
Gland Pharma |
|||||
|
Rs in Crore |
Dec-20 |
Dec-19 |
YOY |
Sep-20 |
QOQ |
|
Total Income (Rs cr) |
₹ 859.42 |
₹ 645.94 |
33.05% |
₹ 831.50 |
3.36% |
|
Operating Profit (Rs cr) |
₹ 239.27 |
₹ 187.54 |
27.58% |
₹ 273.04 |
-12.37% |
|
Net Profit (Rs cr) |
₹ 204.11 |
₹ 154.10 |
32.45% |
₹ 218.86 |
-6.74% |
|
Diluted EPS (Rs) |
₹ 12.82 |
₹ 9.95 |
₹ 14.12 |
||
|
OPM |
27.84% |
29.03% |
32.84% |
||
|
Net Margins |
23.75% |
23.86% |
26.32% |
||
Key takeaways from the Dec-20 quarter results
-
In terms of geographical mix of revenues, revenues from India were up 25% while revenues from the rest of the world were almost up 3-fold on a smaller base. The core market of the US and Europe saw 24% growth on a yoy basis and accounts for over 70% of the total revenues.
-
In the nine months to Dec-20, Gland Pharma has filed 19 ANDAs, 5 DMFs and got 24 ANDA approvals. It spent Rs.91.5 crore on R&D expense which is nearly 4% of the total turnover in the nine-month period.
Related Tags:
$('#popup_mobile_reg').keypress(function (e) {
var mobileNumber = $("#popup_mobile_reg").val();
var regex = new RegExp("^[0-9]+$");
var str = String.fromCharCode(!e.charCode ? e.which : e.charCode);
if (regex.test(str)) {
if (mobileNumber.length
( With inputs from indiainfoline)
#Gland #Pharma #PAT #yoy #Rs20411cr #top #line #expansion
